Navigation Links
Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
Date:12/17/2009

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors. Both surveyed physicians and patients favor agents with excellent glucose lowering ability and physicians in particular say the most influential attribute would be if an agent could reduce HbA1c levels by two percent.

"Physicians we surveyed also tell us that they prefer an agent with an excellent safety profile, which is not surprising given the cardiovascular safety concerns associated with GlaxoSmithKline's Avandia and the more recent pancreatitis association with both Amylin/Eli Lilly's Byetta and Merck's Januvia," stated Nicole Westphal, Ph.D., analyst and product manager at Decision Resources. "For surveyed type 2 diabetes patients, an emerging therapy with disease modifying potential (one that improves the function of insulin producing cells) is also highly desirable."

The new report entitled Brand Perceptions in Noninsulin Antidiabetics also identifies segments of physicians and type 2 diabetes patients that each uses a different mix of criteria to make treatment decisions. The physician segment comprised of young, urban, weight-conscious specialists favor Byetta and will likely drive adoption of new GLP-1 analogues such as, Novo Nordisk/Scios's Victoza and Alkermes/Amylin/Eli Lilly's Byetta LAR. Given this segment's reliance on clinical evidence to drive decisions, this physician segment is an ideal target for companies developing novel drugs.

"The majority of surveyed physicians predict that out of these two agents, Byetta LAR will have the most significant impact on type 2 diabetes treatment, likely because of their familiarity with and comfort prescribing Byetta (Byetta LAR has the same active molecule as Byetta) and their opinion that Byetta LAR (once-weekly injection) offers substantial dosing advantage over Victoza (once-daily injection)," added Dr. Westphal.

The report contains primary research based on a survey of 148 U.S. physicians and 336 U.S. patients. Key brands included in the primary research consist of Byetta; Takeda's Actos, ACTOplus met and Duetact; GlaxoSmithKline's Avandia, Avandamet and Avandaryl; Merck's Januvia and Janumet; and Bristol-Myers Squibb/AstraZeneca/Otsuka's Onglyza.

About Brand Perception Series

Decision Resources' Brand Perception Series quantitatively analyzes physician and patient brand perception of current and emerging therapies and identifies key physician and patient segments to help clients identify high opportunity targets. The findings are driven by extensive primary research and offer clients an unbiased, comprehensive, cost-effective solution to understanding the full competitive brand landscape.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
2. $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers
3. Russias Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
4. Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
5. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
6. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
7. Burton Medicals New Diagnostic Examination Light, the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life
8. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
9. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
10. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
11. Abbott Cuts Use of Oil and Coal by 35 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... -- On 28 May, 194 Member States made ... the 69 th World Health Assembly, governments unanimously voted ... the greatest global commitment in viral hepatitis to date. ... and C by 2030 and includes a set of prevention ... by 65% and increase treatment to 80%, saving 7.1 million ...
(Date:5/30/2016)... 2016 LifeScienceIndustryResearch.com adds "Ulcerative ... report with comprehensive information on the therapeutic development ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Ulcerative ...
(Date:5/27/2016)... -- A new study highlights the necessity of health literacy within the technology advancement of ... of Radiology , a majority of oncology patients undergo imaging screenings without understanding the ... ... ... Medical Diagnostic Imaging Ampronix ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in ... Networks Co., the leading provider of secure mobile remote access solution for Japan ... leading CACHATTO remote access solution. Splashtop for CACHATTO will be available as ...
(Date:5/31/2016)... ... May 31, 2016 , ... The ... advanced Artificial Intelligence (AI) and the latest in Clinical Patient Pod ... integrating predictive analytic outputs directly into the clinical workflow. These insights are empowering ...
(Date:5/31/2016)... Maryland (PRWEB) , ... May 31, 2016 , ... ... to attribute calls back to particular advertising campaigns, to monitor the performance of ... that they can maximize conversions and revenue. The software allows customers to record, ...
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... San Francisco, CA (PRWEB) , ... May 31, 2016 , ... ... and cases for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit ... lightweight, durable waxed canvas or ballistic nylon, the Duo is smartly designed ...
Breaking Medicine News(10 mins):